| Ytd | -50.29% | |
| 1y | -25.54% |
| Open | 1.72 | Prev Close | 1.72 | Low | 1.70 | High | 1.78 | Mkt Cap | 73.28M |
| Vol | 423.32K | Avg Vol | 808.01K | EPS | -1.75 | P/E | N/A | Forward P/E | -2.77 |
| Beta | 1.25 | Short Ratio | 6.21 | Inst. Own | 8.83% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-18 | 50-d Avg | 1.80 | 200-d Avg | 2.48 | 1yr Est | 34.80 |
ANVS News
Roth Capital analyst Boobalan Pachaiyappan maintains Annovis Bio (NYSE:ANVS) with a Buy and lower
MALVERN, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Co
Annovis Bio (NYSE:ANVS) reported quarterly losses of $(0.40) per share which beat the analyst consen
MALVERN, Pa., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Co
Roth Capital analyst Boobalan Pachaiyappan initiates coverage on Annovis Bio (NYSE:ANVS) with a B
Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 34.7% to $0.96 during Tuesday's
Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage
Pivotal Phase 3 trial enrolls 850 patients, exceeding original projections Study completion on track
MALVERN, Pa., July 01, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Co
MALVERN, Pa., May 26, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Com
Each warrant will be exercisable for one share of common stock at an exercise price of $2.25 per sha
MALVERN, Pa., May 20, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Com
Shares of 8x8 Inc (NASDAQ: EGHT) jumped 13.3% in pre-market trading after reporting better-than-expe
MALVERN, Pa., May 19, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Com
Annovis Bio (NYSE:ANVS) reported quarterly losses of $(0.63) per share which missed the analyst cons
Phase 3 AD trial: 85% of patients enrolled; full enrollment on track in summer 2026 PD open-label ex
MALVERN, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Com
Buntanetap improved cognition in pTau217-positive early AD patientsThe drug reduced neurotoxic prote
Buntanetap improved cognition in pTau217-positive early AD patients The drug reduced neurotoxic prot
Financing secures path to first NDA submission for buntanetap6-Month symptomatic data readout antici
MALVERN, Pa., April 10, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “C
MALVERN, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “C
Annovis Bio, Inc. (NYSE: ANVS - Get Free Report) Director Michael Hoffman bought 713,800 shares of t
Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage
MALVERN, Pa., April 02, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “C
MALVERN, Pa., March 31, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “C
NeuroRPM, a digital health company focused on Parkinson's disease monitoring, today announced th
MALVERN, Pa., March 19, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “C
NeuroRPM's AI-enabled Apple Watch-based platform will provide continuous digital biomarker monitorin
Annovis Bio (NYSE:ANVS) reported quarterly losses of $(0.39) per share which missed the analyst cons
MALVERN, Pa., March 16, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “C
MALVERN, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “C
MALVERN, Pa., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Co
Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical dr
Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical d
Annovis Bio rises after Phase 3 data show buntanetap halted decline in Parkinson's patients, wit
Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical d
Annovis Bio (NYSE:ANVS) reported quarterly losses of $(0.37) per share which missed the analyst cons
Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical d
Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical dr
Canaccord Genuity analyst Sumant Kulkarni maintains Annovis Bio (NYSE:ANVS) with a Buy and mainta
Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical dr
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Annovis Bio (NYSE:ANVS) with a Buy a